Aquestive Therapeutics (AQST) Liabilities and Shareholders Equity (2017 - 2026)

Aquestive Therapeutics' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $141.1 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 38.04% year-over-year to $141.1 million; the TTM figure through Mar 2026 stood at $558.8 million (up 29.59% YoY), while the FY2025 annual figure was $160.4 million, up 58.17% from the prior year.
• Liabilities and Shareholders Equity was $141.1 million for Q1 2026 at Aquestive Therapeutics, down from $160.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $163.6 million in Q3 2025 to a low of $51.8 million in Q3 2022.
• Historically, Liabilities and Shareholders Equity has averaged $92.7 million across 5 years, with a median of $93.7 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity jumped 111.35% in 2024, then dropped 21.07% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $57.1 million in 2022, then advanced by 0.61% to $57.4 million in 2023, then soared by 76.64% to $101.4 million in 2024, then soared by 58.17% to $160.4 million in 2025, then slipped by 12.03% to $141.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $141.1 million (Q1 2026), $160.4 million (Q4 2025), and $163.6 million (Q3 2025), per Business Quant data.